Phase II study of docetaxel in the treatment of patients with advanced non-small cell lung cancer in routine daily practice
Details
Serval ID
serval:BIB_E925A77511CE
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Phase II study of docetaxel in the treatment of patients with advanced non-small cell lung cancer in routine daily practice
Journal
Lung Cancer
ISSN
0169-5002 (Print)
Publication state
Published
Issued date
09/2000
Volume
29
Number
3
Pages
205-16
Notes
Clinical Trial
Clinical Trial, Phase II
Journal Article
Research Support, Non-U.S. Gov't --- Old month value: Sep
Clinical Trial, Phase II
Journal Article
Research Support, Non-U.S. Gov't --- Old month value: Sep
Abstract
The purpose of this study was to evaluate the efficacy and safety of docetaxel as first- and second-line chemotherapy for advanced non-small cell lung cancer (NSCLC) under routine clinical conditions. Two hundred and three patients with advanced NSCLC received docetaxel 100 mg/m2 (1-h intravenous infusion) every 3 weeks, with oral corticosteroid pre-medication, of whom 173 were eligible. Median age was 60 (29-78) years and median Karnofsky performance status was 80% (60-100). A total of 77% of patients had metastatic disease, 33% had bone metastases and 18% had liver metastases. The treatment was second-line or more for 72 patients (35%). Overall response rates in the eligible population were 19.7% [95% CI, 12.5-23.0] for both treatments, 22.6% for first-line treatment and 13.8% for second-line treatment. Median survival was 8.3 months and 1-year survival was 35% for the overall population (8.7 months and 38%, respectively, for patients receiving first-line treatment and 7.2 months and 27%, respectively, for patients receiving second-line treatment). Neutropenia, grade 3 and 4, occurred in 57% of the cycles and 5% of patients experienced febrile neutropenia. Alopecia (62% of patients), neuro-sensory symptoms (32%), asthenia (28%), diarrhea (22%), nausea (22%) and nail disorders (20%) were the most common non-hematological adverse effects. A total of 33% of patients suffered fluid retention, despite the use of corticosteroid pre-medication, but this was only severe in 1.5% of patients. It was possible to confirm the efficacy of docetaxel as a single agent for first- and second-line chemotherapy in a large patient population treated in a community setting.
Keywords
Adult
Aged
Antineoplastic Agents, Phytogenic/adverse effects/*therapeutic use
Carcinoma, Non-Small-Cell Lung/*drug therapy/pathology
Female
Humans
Lung Neoplasms/*drug therapy/pathology
Male
Middle Aged
Paclitaxel/adverse effects/*analogs & derivatives/therapeutic use
Survival Analysis
*Taxoids
Treatment Outcome
Pubmed
Web of science
Create date
28/01/2008 9:39
Last modification date
20/08/2019 17:11